BCR::ABL1 Deep Molecular Response Quantification and Transcript Type Identification in Chronic Myeloid Leukemia Using a US Food and Drug Administration–Approved Droplet-Based Digital PCR Assay

Authors: Kockerols, Camille ^∗, Valk, Peter J.M. ^†, Hogenbirk, Pauline ^†, Cornelissen, Jan J. ^†, Westerweel, Peter E. ^{∗, ∗}

Source: In The Journal of Molecular Diagnostics February 2025 27(2):109-118

STAG2 mutations reshape the cohesin-structured spatial chromatin architecture to drive gene regulation in acute myeloid leukemia

Authors: Fischer, Alexander ^{1, 2}, Hernández-Rodríguez, Benjamín ³, Mulet-Lazaro, Roger ^{4, 5}, Nuetzel, Margit ¹, Hölzl, Fabian ², van Herk, Stanley ^{4, 5}, Kavelaars, François G. ⁴, Stanewsky, Hanna ¹, Ackermann, Ute ¹, Niang, Amadou H. ³, Diaz, Noelia ^{3, 9}, Reuschel, Edith ⁶, Strieder, Nicholas ², Hernández-López, Inmaculada ², Valk, Peter J.M. ⁴, Vaquerizas, Juan M. ^{3, 7, 8}, Rehli, Michael ^{1, 2, 10}, Delwel, Ruud ^{4, 5, 10}, Gebhard, Claudia ^{2, 10, 11, ∗}

Source: In Cell Reports 27 August 2024 43(8)

EXABS-100-AML Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?

Authors: Valk, Peter J.M. ^{1, ∗}

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S3-S5

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Authors: Grob, Tim ^*, Al Hinai, Adil S.A. ^*, Sanders, Mathijs A., Kavelaars, François G., Rijken, Melissa, Gradowska, Patrycja L., Biemond, Bart J., Breems, Dimitri A., Maertens, Johan, van Marwijk Kooy, Marinus, Pabst, Thomas, de Weerdt, Okke, Ossenkoppele, Gert J., van de Loosdrecht, Arjan A., Huls, Gerwin A., Cornelissen, Jan J., Beverloo, H. Berna, Löwenberg, Bob, Jongen-Lavrencic, Mojca, Valk, Peter J.M. ^*

Source: In Blood 14 April 2022 139(15):2347-2354

CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Authors: Taube, Franziska ^*, Georgi, Julia Annabell ^*, Kramer, Michael, Stasik, Sebastian, Middeke, Jan Moritz, Röllig, Christoph, Krug, Utz, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Brümmendorf, Tim H., Naumann, Ralph, Petzold, Andreas, Mulet-Lazaro, Roger, Valk, Peter J.M., Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Herold, Sylvia, Stölzel, Friedrich, Sockel, Katja, von Bonin, Malte, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, Thiede, Christian ^*

Source: In Blood 6 January 2022 139(1):87-103

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Authors: Heuser, Michael, Freeman, Sylvie D., Ossenkoppele, Gert J., Buccisano, Francesco, Hourigan, Christopher S., Ngai, Lok Lam, Tettero, Jesse M., Bachas, Costa, Baer, Constance, Béné, Marie-Christine, Bücklein, Veit, Czyz, Anna, Denys, Barbara, Dillon, Richard, Feuring-Buske, Michaela, Guzman, Monica L., Haferlach, Torsten, Han, Lina, Herzig, Julia K., Jorgensen, Jeffrey L., Kern, Wolfgang, Konopleva, Marina Y., Lacombe, Francis, Libura, Marta, Majchrzak, Agata, Maurillo, Luca, Ofran, Yishai, Philippe, Jan, Plesa, Adriana, Preudhomme, Claude, Ravandi, Farhad, Roumier, Christophe, Subklewe, Marion, Thol, Felicitas, van de Loosdrecht, Arjan A., van der Reijden, Bert A., Venditti, Adriano, Wierzbowska, Agnieszka, Valk, Peter J.M., Wood, Brent L., Walter, Roland B., Thiede, Christian, Döhner, Konstanze, Roboz, Gail J., Cloos, Jacqueline ^*

Source: In Blood 30 December 2021 138(26):2753-2767

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification

Authors: van der Werf, Inge ^*, Wojtuszkiewicz, Anna ^{*, *}, Meggendorfer, Manja, Hutter, Stephan, Baer, Constance, Heymans, Martijn, Valk, Peter J.M., Kern, Wolfgang, Haferlach, Claudia, Janssen, Jeroen J.W.M., Ossenkoppele, Gert J., Cloos, Jacqueline, Haferlach, Torsten

Source: In Blood Advances 14 September 2021 5(17):3254-3265

Disruption of CSF-1R signaling inhibits growth of AML with inv(16)

Authors: Simonis, Alexander ^*, Russkamp, Norman F. ^*, Mueller, Jan, Wilk, C. Matthias, Wildschut, Mattheus H.E., Myburgh, Renier, Wildner-Verhey van Wijk, Nicole, Mueller, Rouven, Balabanov, Stefan, Valk, Peter J.M., Theocharides, Alexandre P.A., Manz, Markus G. ^*

Source: In Blood Advances 9 March 2021 5(5):1273-1277

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Authors: Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J., Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W., Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J.F.M., Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W.J., Bargetzi, Mario, Klein, Saskia K., Gadisseur, Alain, Westerweel, Peter E., Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A., Hoogendoorn, Mels, Legdeur, Marie-Cecile J.C., Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T., Janssen, Jeroen J.W.M., Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J.M., van Elssen, Catharina H.M.J., Manz, Markus G., Floisand, Yngvar, Ossenkoppele, Gert J.

Source: In Blood Advances 23 February 2021 5(4):1110-1121

Secondary CNL after SAA reveals insights in leukemic transformation of bone marrow failure syndromes

Authors: Schmied, Laurent ^*, Olofsen, Patricia A. ^*, Lundberg, Pontus, Tzankov, Alexandar, Kleber, Martina, Halter, Jörg, Uhr, Mario, Valk, Peter J.M., Touw, Ivo P., Passweg, Jakob, Drexler, Beatrice

Source: In Blood Advances 10 November 2020 4(21):5540-5546

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

Authors: Vadakekolathu, Jayakumar ^*, Lai, Catherine ^*, Reeder, Stephen, Church, Sarah E., Hood, Tressa, Lourdusamy, Anbarasu, Rettig, Michael P., Aldoss, Ibrahim, Advani, Anjali S., Godwin, John, Wieduwilt, Matthew J., Arellano, Martha, Muth, John, Yau, Tung On, Ravandi, Farhad, Sweet, Kendra, Altmann, Heidi, Foulds, Gemma A., Stölzel, Friedrich, Middeke, Jan Moritz, Ciciarello, Marilena, Curti, Antonio, Valk, Peter J.M., Löwenberg, Bob, Gojo, Ivana, Bornhäuser, Martin, DiPersio, John F., Davidson-Moncada, Jan K., Rutella, Sergio

Source: In Blood Advances 27 October 2020 4(20):5011-5024

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Authors: Huls, Gerwin ^*, Chitu, Dana A., Pabst, Thomas, Klein, Saskia K., Stussi, Georg, Griskevicius, Laimonas, Valk, Peter J.M., Cloos, Jacqueline, van de Loosdrecht, Arjan A., Breems, Dimitri, van Lammeren-Venema, Danielle, van Zeventer, Isabelle, Boersma, Rinske, Jongen-Lavrencic, Mojca, Fehr, Martin, Hoogendoorn, Mels, Manz, Markus G., Söhne, Maaike, van Marwijk Kooy, Rien, Deeren, Dries, van der Poel, Marjolein W.M., Legdeur, Marie Cecile, Tick, Lidwine, Chalandon, Yves, Ammatuna, Emanuele, Blum, Sabine, Löwenberg, Bob, Ossenkoppele, Gert J.

Source: In Blood Advances 22 September 2020 4(18):4267-4277

Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia

Authors: Ottema, Sophie ^{1, 2, *}, Mulet-Lazaro, Roger ^{1, 2, *}, Beverloo, H. Berna ³, Erpelinck, Claudia ^{1, 2}, van Herk, Stanley ^{1, 2}, van der Helm, Robert ³, Havermans, Marije ^{1, 2}, Grob, Tim ¹, Valk, Peter J.M. ¹, Bindels, Eric ¹, Haferlach, Torsten ⁴, Haferlach, Claudia ⁴, Smeenk, Leonie ^{1, 2}, Delwel, Ruud ^{1, 1, 2}

Source: In Blood 9 July 2020 136(2):224-234

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations

Authors: Jutzi, Jonas Samuel, Basu, Titiksha, Pellmann, Maximilian, Kaiser, Sandra, Steinemann, Doris, Sanders, Mathijs A., Hinai, Adil S.A., Zeilemaker, Annelieke, Bojtine Kovacs, Sarolta, Koellerer, Christoph, Ostendorp, Jenny, Aumann, Konrad, Wang, Wei, Raffoux, Emmanuel, Cassinat, Bruno, Bullinger, Lars, Schlegelberger, Brigitte, Valk, Peter J.M., Pahl, Heike Luise ^*

Source: In Blood 18 April 2019 133(16):1766-1777

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients

Authors: Christen, Friederike ^*, Hoyer, Kaja ^*, Yoshida, Kenichi ^*, Hou, Hsin-An ^*, Waldhueter, Nils, Heuser, Michael, Hills, Robert K., Chan, Willy, Hablesreiter, Raphael, Blau, Olga, Ochi, Yotaro, Klement, Piroska, Chou, Wen-Chien, Blau, Igor-Wolfgang, Tang, Jih-Luh, Zemojtel, Tomasz, Shiraishi, Yuichi, Shiozawa, Yusuke, Thol, Felicitas, Ganser, Arnold, Löwenberg, Bob, Linch, David C., Bullinger, Lars, Valk, Peter J.M., Tien, Hwei-Fang, Gale, Rosemary E., Ogawa, Seishi, Damm, Frederik ^*

Source: In Blood 7 March 2019 133(10):1140-1151

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML

Authors: Sanders, Mathijs A. ^*, Chew, Edward ^*, Flensburg, Christoffer, Zeilemaker, Annelieke, Miller, Sarah E., al Hinai, Adil S., Bajel, Ashish, Luiken, Bram, Rijken, Melissa, Mclennan, Tamara, Hoogenboezem, Remco M., Kavelaars, François G., Fröhling, Stefan, Blewitt, Marnie E., Bindels, Eric M., Alexander, Warren S., Löwenberg, Bob, Roberts, Andrew W., Valk, Peter J.M., Majewski, Ian J.

Source: In Blood 4 October 2018 132(14):1526-1534

AML-279 Molecularly-Defined De Novo and Secondary Acute Myeloid Leukemia Are Biologically and Clinically Different Entities

Authors: Boertjes, Emma, Hinai, Adil Al, Stoetman, Elodie, Compagne, Kyra G., Grob, Tim, Kavelaars, Francois G., Rijken, Melissa, Sanders, Mathijs, Beverloo, Berna H., Löwenberg, Bob, Valk, Peter J.M.

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S232-S232

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Authors: Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, van Norden, Yvette, Biemond, Bart J., Schouten, Harry C., Spertini, Olivier, Vellenga, Edo, Graux, Carlos, Havelange, Violaine, de Greef, Georgine E., de Weerdt, Okke, Legdeur, Marie-Cecile J.C., Kuball, Juergen, Kooy, Marinus van Marwijk, Gjertsen, Bjorn T., Jongen-Lavrencic, Mojca, van de Loosdrecht, Arjan A., van Lammeren-Venema, Daniëlle, Hodossy, Beata, Breems, Dimitri A., Chalandon, Yves, Passweg, Jakob, Valk, Peter J.M., Manz, Markus G., Ossenkoppele, Gert J.

Source: In Blood 23 March 2017 129(12):1636-1645

MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome

Authors: Stavropoulou, Vaia, Kaspar, Susanne, Brault, Laurent, Sanders, Mathijs A., Juge, Sabine, Morettini, Stefano, Tzankov, Alexandar, Iacovino, Michelina, Lau, I-Jun, Milne, Thomas A., Royo, Hélène, Kyba, Michael, Valk, Peter J.M., Peters, Antoine H.F.M., Schwaller, Juerg

Source: In Cancer Cell 11 July 2016 30(1):43-58

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia

Authors: Kühnl, Andrea, Valk, Peter J.M., Sanders, Mathijs A., Ivey, Adam, Hills, Robert K., Mills, Ken I., Gale, Rosemary E., Kaiser, Martin F., Dillon, Richard, Joannides, Melanie, Gilkes, Amanda, Haferlach, Torsten, Schnittger, Susanne, Duprez, Estelle, Linch, David C., Delwel, Ruud, Löwenberg, Bob, Baldus, Claudia D., Solomon, Ellen, Burnett, Alan K., Grimwade, David ^*

Source: In Blood 7 May 2015 125(19):2985-2994